Artículos de revistas sobre el tema "B-cell malignancie"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "B-cell malignancie".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Miao, Miao, Wu Depei, Aining Sun, Ying Wang, Lingzhi Yan y Qian Wu. "The Efficacy and Safety of Recombinant Human Thrombopoietin in Patients with Hematological Malgnancies After Allogeneic Hematopoietic Stem Cell Transplantation". Blood 118, n.º 21 (18 de noviembre de 2011): 4565. http://dx.doi.org/10.1182/blood.v118.21.4565.4565.
Texto completoLydyard, Peter M., Andrew P. Jewell, Christoph Jamin y Pierre Y. Youinou. "CD5 B cells and B-cell malignancies". Current Opinion in Hematology 6, n.º 1 (enero de 1999): 30. http://dx.doi.org/10.1097/00062752-199901000-00006.
Texto completoZweidler-McKay, Patrick A., Yiping He, Lanwei Xu, Carlos G. Rodriguez, Fredrick G. Karnell, Andrea C. Carpenter, Jon C. Aster, David Allman y Warren S. Pear. "Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies". Blood 106, n.º 12 (1 de diciembre de 2005): 3898–906. http://dx.doi.org/10.1182/blood-2005-01-0355.
Texto completoBrudno, Jennifer N., Robert P. T. Somerville, Victoria Shi, Jeremy J. Rose, David C. Halverson, Daniel H. Fowler, Juan C. Gea-Banacloche et al. "Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease". Journal of Clinical Oncology 34, n.º 10 (1 de abril de 2016): 1112–21. http://dx.doi.org/10.1200/jco.2015.64.5929.
Texto completoRen, Anqi, Xiqin Tong, Na Xu, Tongcun Zhang, Fuling Zhou y Haichuan Zhu. "CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities". Vaccines 11, n.º 1 (12 de enero de 2023): 165. http://dx.doi.org/10.3390/vaccines11010165.
Texto completoHudecek, Michael, Thomas M. Schmitt, Sivasubramanian Baskar, Maria Teresa Lupo-Stanghellini, Tetsuya Nishida, Tori N. Yamamoto, Marie Bleakley et al. "The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor". Blood 116, n.º 22 (25 de noviembre de 2010): 4532–41. http://dx.doi.org/10.1182/blood-2010-05-283309.
Texto completoChattaraj, Asmi, Mohammad Ebad Ur Rehman, Israr Khan, Diana Franco, Atif Ibrahim, Razwana Khanam, Nayha Tahir et al. "Safety and efficacy of allogeneic CAR-T cells in B-cell malignancies: A systematic review and meta-analysis." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e19530-e19530. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e19530.
Texto completoTonino, Sanne H., Marinus H. J. Van Oers, Rene A. Van Lier y Marie Jose Kersten. "CMV-Associated Expansion of CD8+CD45RA+CD27− T-Cells in Patients with B-Cell Malignancies." Blood 110, n.º 11 (16 de noviembre de 2007): 3592. http://dx.doi.org/10.1182/blood.v110.11.3592.3592.
Texto completoIncrocci, Ryan, Molly McCormack y Michelle Swanson-Mungerson. "Epstein–Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas". Journal of General Virology 94, n.º 5 (1 de mayo de 2013): 1127–33. http://dx.doi.org/10.1099/vir.0.049221-0.
Texto completoPrakash, Ajay y Alhossain A. Khalafallah. "Concurrent Hairy Cell Leukemia and Metastatic Merkel Cell Carcinoma". Case Reports in Oncological Medicine 2018 (14 de noviembre de 2018): 1–6. http://dx.doi.org/10.1155/2018/1736854.
Texto completoMaio, M., A. Pinto, A. Carbone, V. Zagonel, A. Gloghini, G. Marotta, D. Cirillo, A. Colombatti, F. Ferrara y L. Del Vecchio. "Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders". Blood 76, n.º 4 (15 de agosto de 1990): 783–90. http://dx.doi.org/10.1182/blood.v76.4.783.783.
Texto completoMaio, M., A. Pinto, A. Carbone, V. Zagonel, A. Gloghini, G. Marotta, D. Cirillo, A. Colombatti, F. Ferrara y L. Del Vecchio. "Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders". Blood 76, n.º 4 (15 de agosto de 1990): 783–90. http://dx.doi.org/10.1182/blood.v76.4.783.bloodjournal764783.
Texto completoSwanson-Mungerson, Michelle, Ryan Incrocci, Molly McCormack y Caroline Leof. "Effects of Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) on cytokine production in primary and transformed B cells (105.40)". Journal of Immunology 188, n.º 1_Supplement (1 de mayo de 2012): 105.40. http://dx.doi.org/10.4049/jimmunol.188.supp.105.40.
Texto completoKochenderfer, James N., Mark E. Dudley, Robert O. Carpenter, Sadik H. Kassim, Jeremy J. Rose, William Telford, Frances T. Hakim et al. "Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation". Blood 122, n.º 21 (15 de noviembre de 2013): 151. http://dx.doi.org/10.1182/blood.v122.21.151.151.
Texto completoDalla Pietà, Anna, Elisa Cappuzzello, Pierangela Palmerini, Annavera Ventura, Andrea Visentin, Giuseppe Astori, Katia Chieregato et al. "Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells". Journal for ImmunoTherapy of Cancer 9, n.º 7 (julio de 2021): e002475. http://dx.doi.org/10.1136/jitc-2021-002475.
Texto completoLi, Yangqiu, Lijian Yang, Shaohua Chen, Suxia Geng, Grzegorz Przybylski y Christian A. Schmidt. "Changes in Thymic Recent Output Function in Patients with B-Cell Lymphocytic Malignancy." Blood 108, n.º 11 (16 de noviembre de 2006): 4464. http://dx.doi.org/10.1182/blood.v108.11.4464.4464.
Texto completoLink, BK y GJ Weiner. "Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells". Blood 81, n.º 12 (15 de junio de 1993): 3343–49. http://dx.doi.org/10.1182/blood.v81.12.3343.bloodjournal81123343.
Texto completoSud, Amit, Subhayan Chattopadhyay, Hauke Thomsen, Kristina Sundquist, Jan Sundquist, Richard S. Houlston y Kari Hemminki. "Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk". Blood 134, n.º 12 (8 de agosto de 2019): 960–69. http://dx.doi.org/10.1182/blood.2019001362.
Texto completoGreen, Michael R. y Ash A. Alizadeh. "Common progenitor cells in mature B-cell malignancies". Current Opinion in Hematology 21, n.º 4 (julio de 2014): 333–40. http://dx.doi.org/10.1097/moh.0000000000000049.
Texto completoYazdani, Yaghoub, Mousa Mohammadnia-Afrouzi, Mehdi Yousefi, Enayat Anvari, Ghasem Ghalamfarsa, Hadi Hasannia, Sanam Sadreddini y Farhad Jadidi-Niaragh. "Myeloid-derived suppressor cells in B cell malignancies". Tumor Biology 36, n.º 10 (2 de septiembre de 2015): 7339–53. http://dx.doi.org/10.1007/s13277-015-4004-z.
Texto completoCooper, Kathrine A., Jonathan Lattell, Beverly Gonzalez, Stephanie Kliethermes y Sucha Nand. "Prevalence of Multiple Primary Hematologic Malignancies Seen at a Tertiary Care Center". Blood 126, n.º 23 (3 de diciembre de 2015): 5017. http://dx.doi.org/10.1182/blood.v126.23.5017.5017.
Texto completoKroeze, Emma, Laura Arias Padilla, Max Bakker, Judith M. Boer, Melanie M. Hagleitner, Birgit Burkhardt, Takeshi Mori et al. "Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement". Cancers 14, n.º 16 (12 de agosto de 2022): 3895. http://dx.doi.org/10.3390/cancers14163895.
Texto completoLink, BK y GJ Weiner. "Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells". Blood 81, n.º 12 (15 de junio de 1993): 3343–49. http://dx.doi.org/10.1182/blood.v81.12.3343.3343.
Texto completoJacobs, Lauren M., Peter H. Wiernik, Janice P. Dutcher y Pablo Muxi. "Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab". Journal of Investigative Medicine High Impact Case Reports 5, n.º 1 (enero de 2017): 232470961769130. http://dx.doi.org/10.1177/2324709617691307.
Texto completoWeng, Jinsheng, Flavio Egidio Baio, Kelsey E. Moriarty, Hiroki Torikai, Hua Wang, Zhiqiang Liu, Sourindra N. Maiti et al. "Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells". OncoImmunology 5, n.º 11 (19 de septiembre de 2016): e1232220. http://dx.doi.org/10.1080/2162402x.2016.1232220.
Texto completoGhimire, Krishna B. y Binay K. Shah. "Second Primary Malignancy in Diffuse Large B Cell Lymphoma (DLBCL)". Blood 124, n.º 21 (6 de diciembre de 2014): 2606. http://dx.doi.org/10.1182/blood.v124.21.2606.2606.
Texto completoSabbah, Shereen, Ya Jankey Jagne, Jianmin Zuo, Thushan de Silva, Mohammad M. Ahasan, Christian Brander, Sarah Rowland-Jones, Katie L. Flanagan y Andrew D. Hislop. "T-cell immunity to Kaposi sarcoma–associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells". Blood 119, n.º 9 (1 de marzo de 2012): 2083–92. http://dx.doi.org/10.1182/blood-2011-07-366476.
Texto completoZhao, Zhigang, Lin Li, Meelad Dawlaty, Feng Pan, Zhe Li, Yuan Zhou, Hui Shi et al. "Combined Loss of Tet1 and Tet2 Promotes B-Cell, but Not Myeloid Malignancies in Mice". Blood 126, n.º 23 (3 de diciembre de 2015): 3650. http://dx.doi.org/10.1182/blood.v126.23.3650.3650.
Texto completoChintapatla, Rangaswamy, Leticia Varella, Peter Wiernik, Valerie Rusciano y Janice P. Dutcher. "Association of Renal Cell Carcinoma and B-Cell Hematological Malignancy". Blood 120, n.º 21 (16 de noviembre de 2012): 5086. http://dx.doi.org/10.1182/blood.v120.21.5086.5086.
Texto completoZhang, Jenny, Dereje D. Jima, Yuan Gao, Han Wu, Jun Zhu, Mark deLong, Peter E. Lipsky y Sandeep S. Dave. "Massively Parallel High Throughput Sequencing Identifies Novel Micrornas in Normal and Malignant B Cells." Blood 112, n.º 11 (16 de noviembre de 2008): 3350. http://dx.doi.org/10.1182/blood.v112.11.3350.3350.
Texto completoMiletic, Ana V., Amy N. Anzelon-Mills, David M. Mills, Sidne A. Omori, Irene M. Pedersen, Dong-Mi Shin, Jeffrey V. Ravetch, Silvia Bolland, Herbert C. Morse y Robert C. Rickert. "Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases". Journal of Experimental Medicine 207, n.º 11 (18 de octubre de 2010): 2407–20. http://dx.doi.org/10.1084/jem.20091962.
Texto completoChen, Zhengshan y Markus Muschen. "Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies". Blood 132, Supplement 1 (29 de noviembre de 2018): 1587. http://dx.doi.org/10.1182/blood-2018-99-113674.
Texto completoLichtman, Eben I. y Gianpietro Dotti. "Chimeric antigen receptor T-cells for B-cell malignancies". Translational Research 187 (septiembre de 2017): 59–82. http://dx.doi.org/10.1016/j.trsl.2017.06.011.
Texto completoMichels, Kathryn R., Alyssa Sheih, Susana A. Hernandez, Alissa H. Brandes, Don Parrilla, Blythe Irwin, Anai M. Perez et al. "Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering". Journal for ImmunoTherapy of Cancer 11, n.º 3 (marzo de 2023): e006292. http://dx.doi.org/10.1136/jitc-2022-006292.
Texto completoZhang, Jenny, Dereje D. Jima, Cassandra Jacobs, Randy Fischer, Eva Gottwein, Grace Huang, Patricia L. Lugar et al. "Patterns of microRNA expression characterize stages of human B-cell differentiation". Blood 113, n.º 19 (7 de mayo de 2009): 4586–94. http://dx.doi.org/10.1182/blood-2008-09-178186.
Texto completoYavuz, Selim A., Dan-Paul Hartmann, Said Baidas, Peter E. Lipsky y Metin Ozdemirli. "Demonstration of Biclonal Chronic Lymphocytic Leukemia with Mutated and Unmutated Clones and Concurrent but Clonally Unrelated Myeloma in the Same Patient by Single Cell Immunoglobulin Heavy and Light Chain Gene Analysis." Blood 104, n.º 11 (16 de noviembre de 2004): 4772. http://dx.doi.org/10.1182/blood.v104.11.4772.4772.
Texto completoChen, Weili, Quanzhi Li, Wendy A. Hudson, Ashish Kumar, Nicole Kirchhof y John H. Kersey. "A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy". Blood 108, n.º 2 (15 de julio de 2006): 669–77. http://dx.doi.org/10.1182/blood-2005-08-3498.
Texto completoLinden, Michael, Nicole Kirchhof, Cathy Carlson y Brian Van Ness. "Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies". Blood 103, n.º 7 (1 de abril de 2004): 2779–86. http://dx.doi.org/10.1182/blood-2003-10-3399.
Texto completoKong, Ling-Yuan, Vaibhav Kapuria, Geoffrey Bartholomeusz, Moshe Talpaz, Waldemar Priebe y Nicholas J. Donato. "Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma." Blood 106, n.º 11 (16 de noviembre de 2005): 1489. http://dx.doi.org/10.1182/blood.v106.11.1489.1489.
Texto completoDas, Manjulika. "Zanubrutinib in B-cell malignancies". Lancet Oncology 20, n.º 9 (septiembre de 2019): e470. http://dx.doi.org/10.1016/s1470-2045(19)30523-6.
Texto completoHillis, Jennifer, Michael O’Dwyer y Adrienne M. Gorman. "Neurotrophins and B-cell malignancies". Cellular and Molecular Life Sciences 73, n.º 1 (23 de septiembre de 2015): 41–56. http://dx.doi.org/10.1007/s00018-015-2046-4.
Texto completoNovero, Aileen, Pavan M. Ravella, Yamei Chen, George Dous y Delong Liu. "Ibrutinib for B cell malignancies". Experimental Hematology & Oncology 3, n.º 1 (2014): 4. http://dx.doi.org/10.1186/2162-3619-3-4.
Texto completoOwen, Carolyn J. y Douglas A. Stewart. "Obinutuzumab for B-cell malignancies". Expert Opinion on Biological Therapy 14, n.º 8 (23 de mayo de 2014): 1197–205. http://dx.doi.org/10.1517/14712598.2014.922535.
Texto completoAbuHilal, Mohanad, Scott Walsh y Neil Shear. "Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study". Journal of Cutaneous Medicine and Surgery 21, n.º 6 (14 de junio de 2017): 507–12. http://dx.doi.org/10.1177/1203475417716366.
Texto completoPongas, Georgios y Bruce D. Cheson. "PI3K signaling pathway in normal B cells and indolent B-cell malignancies". Seminars in Oncology 43, n.º 6 (diciembre de 2016): 647–54. http://dx.doi.org/10.1053/j.seminoncol.2016.11.011.
Texto completoElsawa, Sherine F., Anne J. Novak, Deanna M. Grote, Steven C. Ziesmer, Thomas E. Witzig, Robert A. Kyle, Stacey R. Dillon, Brandon Harder, Jane A. Gross y Stephen M. Ansell. "B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia". Blood 107, n.º 7 (1 de abril de 2006): 2882–88. http://dx.doi.org/10.1182/blood-2005-09-3552.
Texto completoQian, Jin. "Immune escape mechanism of B-cell malignancies on Anti-CD19 Chimeric Antigen Receptor T-cell treatment and solution". E3S Web of Conferences 271 (2021): 03038. http://dx.doi.org/10.1051/e3sconf/202127103038.
Texto completoBrown, Jennifer R., Heather Yeckes, Jonathan W. Friedberg, Donna Neuberg, Helen Kim, Lee M. Nadler y Arnold S. Freedman. "Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin’s Lymphoma". Journal of Clinical Oncology 23, n.º 10 (1 de abril de 2005): 2208–14. http://dx.doi.org/10.1200/jco.2005.05.158.
Texto completoTaghi Khani, Adeleh, Anil Kumar, Kelly Radecki, Sung June Lee, Mary Lorenson, Xiwei Wu, Zhaohui Gu, Ameae Walker y Srividya Swaminathan. "Suppressing Synthesis of the Long Isoform of the Prolactin Receptor Is a Targeted Strategy to Prevent and Treat B Cell Malignancies". Blood 138, Supplement 1 (5 de noviembre de 2021): 1135. http://dx.doi.org/10.1182/blood-2021-147055.
Texto completoGreenberg, Zev J., Darlene A. Monlish, Rachel L. Bartnett y Laura G. Schuettpelz. "Regulation of Homeostatic and Malignant B Cell Development By the Tetraspanin CD53". Blood 132, Supplement 1 (29 de noviembre de 2018): 3699. http://dx.doi.org/10.1182/blood-2018-99-111957.
Texto completo